Ablynx, which is developing single domain antibodies derived from llamas for various diseases, raised $200 million in the US by offering 11.4 million shares at $17.50 (€14.88), a discount to its prior closing price on Euronext Brussels (€16.25; ticker ABLX BB). It had previously planned to offer $150 million worth of shares in the US and concurrently offer $25 million worth of shares in a European private placement. At the IPO price, Ablynx commands a fully diluted market value of $1.29 billion (€1.10 billion). Ablynx plans to list on the Nasdaq under the symbol ABLX. BofA Merrill Lynch, J.P. Morgan and Jefferies acted as lead managers on the deal.
